Synendos Therapeutics Expands Series A to CHF 24 million with new investment. Ysios Capital joins other investors

by Ysios Capital

Synendos Therapeutics (Synendos), a biopharmaceutical company focused on restoring the natural functioning of the endocannabinoid system to treat Central Nervous System (CNS) disorders, announces an e...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

tuTECHÔ se convierte en la primera empr...

by EY - Ernst & Young

tuTECHÔ, empresa social que lucha contra el sinhogarismo en España, ...

Photos Stream